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Desmosterolosis is a rare autosomal recessive disorder characterized by multiple congenital anomalies. Patients with
desmosterolosis have elevated levels of the cholesterol precursor desmosterol, in plasma, tissue, and cultured cells;
this abnormality suggests a deficiency of the enzyme 3b-hydroxysterolD24-reductase (DHCR24),which, in cholesterol
biosynthesis, catalyzes the reduction of the D24 double bond of sterol intermediates. We identified the human
DHCR24 cDNA, by the similarity between the encoded protein and a recently characterized plant enzyme—DWF1/
DIM, from Arabidopsis thaliana—catalyzing a different but partially similar reaction in steroid/sterol biosynthesis
in plants. Heterologous expression, in the yeast Saccharomyces cerevisiae, of the DHCR24 cDNA, followed by
enzyme-activity measurements, confirmed that it encodes DHCR24. The encoded DHCR24 protein has a calculated
molecular weight of 60.1 kD, contains a potential N-terminal secretory-signal sequence as well as at least one
putative transmembrane helix, and is a member of a recently defined family of flavin adenine dinucleotide
(FAD)–dependent oxidoreductases. Conversion of desmosterol to cholesterol by DHCR24 in vitro is strictly de-
pendent on reduced nicotinamide adenine dinucleotide phosphate and is increased twofold by the addition of FAD
to the assay. The corresponding gene, DHCR24, was identified by database searching, spans ∼46.4 kb, is localized
to chromosome 1p31.1-p33, and comprises nine exons and eight introns. Sequence analysis of DHCR24 in two
patients with desmosterolosis revealed four different missense mutations, which were shown, by functional ex-
pression, in yeast, of the patient alleles, to be disease causing. Our data demonstrate that desmosterolosis is a
cholesterol-biosynthesis disorder caused by mutations in DHCR24.
Introduction
In recent years, several inherited disorders have been
linked to enzyme defects in the isoprenoid/cholesterol
biosynthetic pathway, by the discovery of abnormally
increased levels of intermediate metabolites in patients,
followed by the demonstration that there are disease-
causing mutations in genes encoding the implicated en-
zymes (Schafer et al. 1992; Fitzky et al. 1998; Wassif et
al. 1998; Waterham et al. 1998; Braverman et al. 1999;
Derry et al. 1999; Drenth et al. 1999; Houten et al. 1999;
Konig et al. 2000). The isoprenoid/cholesterol biosyn-
thetic pathway produces numerous molecules that are
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involved in a variety of cell processes, including cell
growth and differentiation, glycosylation, signal trans-
duction, and electron transport (Goldstein and Brown
1990). Most currently identified enzyme defects specif-
ically affect the biosynthesis of cholesterol and lead to
multiple congenital, skeletal, and/or skin abnormalities
(Herman 2000; Kelley 2000; Kelley and Hennekam
2000; Waterham and Wanders 2000).
Isoprenoid/cholesterol biosynthesis starts with the C2
compound acetyl-CoA, which, in a series of six different
enzyme reactions, is converted to isopentenyl-PP, the
basic C5 isoprene unit used for the synthesis of all sub-
sequent isoprenoids (Goldstein and Brown 1990; Wa-
terham and Wanders 2000). The first intermediate com-
mitted to the production of sterols is C30 squalene
(composed of six isoprene units), which, after cycliza-
tion, is converted to lanosterol (4,4,14a-trimethylcho-
lesta-8(9),24-dien-3b-ol). To eventually produce cho-
lesterol from lanosterol, a series of enzyme reactions is
required, including one demethylation at C-14, two de-
methylations at C-4, one isomerization of D8(9) to D7,
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Figure 1 Sterol synthesis in lymphoblasts from the control and from patient 2. A, Synthesis of cholesterol from lanosterol, the first sterol
intermediate produced in the isoprenoid-biosynthetic pathway, in a series of enzymatic steps catalyzed by two demethylases, three reductases,
one isomerase, and one desaturase. Deficiency of either DHCR24 or DHCR7 (as in SLOS or as induced by BM 15.766) results in accumulation
of the sterol intermediates desmosterol or 7-dehydrocholesterol, respectively. A combined deficiency of both sterol reductases results in accu-
mulation of 7-dehydrodesmosterol. B, GC/MS sterol analysis of cultured lymphoblasts. Sterol analysis of lymphoblasts from a control and from
patient 2, cultured in lipoprotein-deficient medium, revealed, in the absence of BM 15.766, accumulation of desmosterol (2) in cells from the
patient, whereas only accumulation of cholesterol (1) was observed in cells from the control. When cultured in the presence of the DHCR7
inhibitor BM 15.766, accumulation of both 7-dehydrocholesterol (3) and 7-dehydrodesmosterol (4) was observed in cells from the patient,
indicating a partial deficiency of DHCR24.
three reductions of the D24, D14, and D7 double bonds,
and one desaturation between C-5 and C-6 (fig. 1A).
Although the various enzyme reactions required for the
conversion of lanosterol to cholesterol have been estab-
lished, their preferred sequence may vary. Consequently,
two major routes involving the same enzymes have been
proposed that postulate, as the ultimate precursor of
cholesterol, either 7-dehydrocholesterol (cholesta-5,7-
dien-3b-ol) or desmosterol (cholesta-5,24-dien-3b-ol),
depending mainly on the timing of the reduction of the
D24 double bond (Frantz and Schroepfer 1967; Bae and
Paik 1997; Waterham and Wanders 2000). It is assumed
that the various enzymes involved in the conversion of
lanosterol to cholesterol, are rather nonspecific and can
handle different intermediates.
The majority of the human genes encoding the var-
ious enzymes involved in cholesterol biosynthesis have
been identified only very recently, as a corollary of the
identification and elucidation of the biochemical and
molecular bases of inherited defects of cholesterol bio-
synthesis. In most cases, the gene identification was
aided by the similarity, in sequence and/or function,
between the human proteins and their orthologs in other
organisms, including yeasts and plants.
We now report the molecular basis of autosomal re-
cessive desmosterolosis (MIM 602398), a severe mul-
tiple-congenital-anomaly syndrome caused by a defect
in cholesterol biosynthesis, as indicated, in patients, by
elevated plasma and tissue levels of the cholesterol pre-
cursor desmosterol (FitzPatrick et al. 1998). Since this
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biochemical abnormality suggested a deficiency of the
cholesterol-biosynthetic enzyme 3b-hydroxysterol D24-
reductase (DHCR24), we undertook to identify the hu-
man gene encoding this enzyme. Although no sterol D24-
reductase gene had been reported for any organism, we
were able to identify the human gene by the sequence
similarity between its encoded protein and a recently
characterized plant enzyme catalyzing a different but
partially similar reaction in steroid/sterol biosynthesis
in plants. Mutation analysis of the DHCR24 gene in
two patients with desmosterolosis revealed different dis-
ease-causing mutations, as demonstrated by expression
in Saccharomyces cerevisiae.
Subjects and Methods
Patients
Two patients previously diagnosed with desmostero-
losis were included in this study: Patient 1 was a female
infant of European descent, born to unrelated parents,
at 34 wk gestation, who died 1 h after birth; she exhib-
ited multiple congenital anomalies, including macro-
cephaly, frontal bossing, hypoplastic nose, posteriorly
rotated low-set ears, cleft palate, micrognathia, ambi-
guity of external genitalia, rhizomelic shortening of the
limbs, malformation of several internal organs, and gen-
eralized osteosclerosis (FitzPatrick et al. 1998). Patient
2 is a 4-year-old male child of European descent, born
to parents not known to be related, who exhibits a phe-
notype less severe than that exhibited by patient 1; his
clinical presentation includes dysmorphic facial features,
microcephaly, limb anomalies, and profound develop-
mental delay (Andersson et al. 2000). Informed consent
to the study of both patients and of parental material
was obtained.
Sterol Analysis of Cultured Cells
Lymphoblasts from a control and from patient 2 were
cultured, for 5 d, in HAM-F10 medium (Gibco) con-
taining 10% delipidated fetal-calf serum (Roche Bio-
chemicals), in the absence or presence of 20 mM BM
15.766 (3b-hydroxysterol D7-reductase [DHCR7] inhib-
itor). For sterol analysis, the lymphoblasts were har-
vested by centrifugation and were saponified, for 2 h at
70C, in alkaline ethanol, after which the sterols were
extracted with hexane, converted to trimethylsilyl de-
rivatives by bis(trimethylsilyl)trifluoroacetamide-trime-
thylchlorosilane, and analyzed by gas chromatography/
mass spectrometry (GC/MS).
Expression, in S. cerevisiae, of human DHCR24 cDNA
Construction of expression plasmids.—For functional
expression studies of DHCR24 proteins, the coding
regions of control and mutant DHCR24 cDNA were
PCR amplified from first-strand cDNA synthesized from
RNA isolated either from cultured primary skin fibro-
blasts from the control or from cultured lymphoblasts
from patient 2, as described elsewhere (IJlst et al. 1994).
Control DHCR24 was amplified from fibroblast cDNA
by primers DHCR244–19 (5
′-ATTAAGCTTCCACCAT-
GGAGCCCGCCGTGTCGC-3′; introducing a HindIII
site) andDHCR241555–1577 (5
′-ATTGAATTCGTCTGTC-
TCTCCAGGCGGGCTCC-3′; introducing an EcoRI
site). The same primer set was used to amplify the E191K
allele from cDNA prepared from lymphoblasts from pa-
tient 2. Since, for patient 1, no cDNA was available, the
Y471S and N294TK306N (combined and separate)
mutations were introduced into the DHCR24 coding
region by means of the megaprimer procedure (Barik
1995). In the first round of PCR amplification, control
DHCR24 cDNA was used as template, primer
DHCR244–19 was used in conjunction with mutation
primer DHCR241412ArC (5
′-GTAGCAGTCGGCAGAC-
AGCATCTGG-3′; introducing Y471S), and primer
DHCR241555–1577 was used in conjunction with mutation
primers DHCR24881ArC (5
′-CAGCAAGCTGACTAGC-
ATTGGC-3′; introducing N294T) and DHCR24918GrC
(5′-CCGTGGTTCTTTAACCATGTGGAGAAC-3′; in-
troducing K306N). In the second round, to generate, by
PCR amplification, the full-length coding regions, con-
trol DHCR24 cDNA was used as template, and the am-
plicons from the first round were used in conjunction
with either primer DHCR241555–1577 (for Y471S) or
primer DHCR244–19 (for N294TK306N). To obtain
the combined N294TK306N allele, the constructed
N294T allele was used, in the second round of ampli-
fication, as a template, with the K306N amplicon and
with primer DHCR244–19. All PCR products used for
expression studies were entirely sequenced—for verifi-
cation and to exclude PCR-introduced errors.
Expression in S. cerevisiae.—For expression in S. cere-
visiae, control and mutant DHCR24 coding sequences
were cloned as HindIII-EcoRI fragments, under tran-
scriptional control of the GAL1 promoter, in the yeast-
expression vector pYES2 (Invitrogen). The resulting ex-
pression plasmids were transformed into S. cerevisiae
strain INVSC2 (Invitrogen), and the expression strains
were cultured at 30C, in yeast-nitrogen base medium
(Difco) supplemented with 20 mg histidine/ml, with 2%
galactose (for induction of the GAL1 promoter) as car-
bon source. After the yeast cultures reached, at 600 nm,
an optical density of ∼1 (i.e., after 15–20 h of growth),
the cells were harvested by centrifugation, washed with
5 mM Tris/HCl (pH 7.5) and 50 mM NaCl buffer, and
resuspended in 500 ml NaCl buffer. Cells were disrupted
by vigorous vortexing ( s, at 4C), after addition5# 60
of 250 ml glass beads.
DHCR24 enzyme-activity measurements.—To assay
for DHCR24 activity, the production of cholesterol from
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Table 1
Primers Used for Mutation Analysis of DHCR24
EXON(S)
PRIMER
(5′r3′)
Forward Reverse
1 [21M13]GAACCTCGGCGACCCGAG [M13rev]CTCCCGTCGCCACCTCGC
2 [21M13]TGCTGGCCAGGGAGGTGC [M13rev]CTGTCCACTCTGCAATGCCC
3 and 4 [21M13]AGCTCCCCTTGGGCCTGG [M13rev]ACCTCCCTGACCTCAGGATC
5 [21M13]TTGCTCCCCCACTGACTGC [M13rev]TCAGGATAGGGGAACCGGC
6 [21M13]TGAAAAGGCCAGGAGTGCTG [M13rev]CTAAGAGCCTGCTGCTTGAAC
7 and 8 [21M13]CCCTTGCACTTGGAGACATTC [M13rev]GCTGGCCTCATTCCCCTGG
9 [21M13]GCTGCAGAATGAGCAGTTGG [M13rev]TGCCCCCTGGAAGCCAGG
desmosterol was measured by incubation of 25 ml of the
resulting homogenates in 225 ml assay mix, for 4 h at
37C. Final concentrations in the enzyme assay were 100
mM Tris/HCl (pH 7.23), 0.1 mM EDTA, 1 mM dithio-
threitol, 30 mM nicotinamide, 3.5 mM nicotinamide ad-
enine dinucleotide phosphate (NADP), 30 mM glucose-
6-phosphate, 2 U glucose-6-phosphate dehydrogenase/
ml (for reduced-nicotinamide-adenine-dinucleotide-phos-
phate [NADPH] [re]generation), 0.5 mg bovine serum
albumin/ml, and 168 mM desmosterol (Sigma; prepared,
as 420 mM stock in 1.25% methyl-b-cyclodextrin [Fluka],
in Tris/HCl [pH 7.23]). After incubation, cholesterol and
desmosterol levels in the assay were analyzed by GC/MS,
by the procedure described above. To correct for inter-
assay differences between homogenate concentrations, the
production of cholesterol from desmosterol was normal-
ized for the cytosolic phosphoglucose isomerase (PGI) ac-
tivity, measured in the same type of yeast homogenates
as that which has been described by Bergmeyer et al.
(1983). For study of the effect that NADPH and flavin
adenine dinucleotide (FAD) have on DHCR24 activity,
yeast homogenates were incubated in the assay mix de-
scribed above—with NADP, without NADP, without
NADP but with the addition of 20 mM FAD, and with
NADP with the addition of 20 mM FAD.
Mutation Analysis
Genomic DNA from the patients, from their parents,
and from control subjects was isolated by the Wizard
genomic DNA purification kit (Promega). The protein-
encoding portions of exons 1 and 9 and the entirety of
exons 2–8 plus flanking intron sequences from the
DHCR24 gene were PCR amplified by primer pairs
tagged with either21M13 (5′-TGTAAAACGACGGC-
CAGT-3′) or M13rev (5′-CAGGAAACAGCTATGACC-
3′). Primer sequences are given in table 1. PCR fragments
were sequenced, in two directions, by “21M13” and
“M13rev” fluorescent primers, on an Applied Biosys-
tems 377A automated DNA sequencer, according to the
manufacturer’s protocol (Perkin Elmer).
Results
Identification of Human DHCR24 cDNA
Previous analysis of postmortem tissues from patient 1
(FitzPatrick et al. 1998) and of plasma from patient 2
(Andersson et al. 2000) revealed a relative deficiency of
cholesterol and markedly elevated levels of its biosynthetic
precursor, desmosterol, indicating a specific impediment
to the conversion of desmosterol to cholesterol. Sterol
analysis of lymphoblasts from patient 2, cultured in de-
lipidated medium in the presence or absence of the
DHCR7 inhibitor BM 15.766, revealed de novo synthesis
of desmosterol and of cholesterol, indicating that, al-
though significant, the impediment in this patient is partial
(fig. 1). The abnormal sterol patterns observed in both
patients suggested a deficiency of DHCR24, the enzyme
catalyzing the reduction of the D24 bond of desmosterol
(as well as other D24-bond–containing sterol intermedi-
ates), producing cholesterol (fig. 2B). To demonstrate this
at the molecular level, we undertook to identify the gene
encoding human DHCR24.
In our search for candidate genes, we noticed two
recent reports describing the biochemical characteriza-
tion of DWARF1/DIMINUTO mutants of Arabidopsis
thaliana—that is, of plants displaying dwarfism and re-
duced fertility (Klahre et al. 1998; Choe et al. 1999).
The mutated DWF1 (or DIM) gene encodes an integral
endoplasmic-reticulum–membrane protein—DWF1—
involved in the biosynthesis of plant sterols and of bras-
sinosteroids; DWF1 catalyzes both the isomerization of
the D24(28) bond to a D24(25) bond and the subsequent
reduction of the D24(25) bond in various sterol/brassino-
steroid precursors (fig. 2A). Both the striking resem-
blance of this latter reduction to that of the D24 bond of
desmosterol (and to that of other D24-bond–containing
sterol intermediates) required for cholesterol production
(fig. 2B) and the existence of a putative human ortholog
of DWF1 (Nomura et al. 1994; Takahashi et al. 1995)
prompted us to study whether this ortholog is human
DHCR24. Comparison of the predicted amino acid se-
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Figure 2 Sterol/steroid biosynthesis in plant and in human. A, DWF1 function in the biosynthetic pathway for plant sterols and steroids
(brassinolide). The enzyme catalyzes both the isomerization of the D24(28) bond into a D24(25) bond and the subsequent reduction of the D24(25)
bond from plant-sterol intermediates 24-methylenecholesterol and isofucosterol, to produce campesterol (plant-steroid precursor) and sitosterol
(major plant sterol), respectively. B, Reduction, by DWF1, of the D24(25) bond from plant-sterol intermediates, which resembles the reduction,
catalyzed by DHCR24 and required for the synthesis of cholesterol, of the D24 bond from desmosterol.
quence of the original human-KIAA0018-cDNA se-
quence (GenBank), with an open reading frame (ORF)
of 1,172 bp, to that of DWF1 suggested a sequence error
(i.e., a cytidine omission at position 1129) leading to the
prediction of a truncated protein species of 391 amino
acids. Indeed, sequencing of part of the 4,149 bp of
cDNA PCR amplified from reverse-transcribed skin-fi-
broblast mRNA established an ORF of 1,548 bp pre-
dicted to encode a polypeptide of 516 amino acids.
To determine whether the DWF1 ortholog is DHCR24,
we expressed the coding sequence in S. cerevisiae, a eu-
karyotic organism devoid of endogenous sterol D24-re-
ductase activity and incapable of cholesterol synthesis.
When we incubated homogenates of the expressing strain
with desmosterol, we observed an efficient conversion of
desmosterol to cholesterol (fig. 3). This conversion was
strictly dependent on NADPH, a result that is in accor-
dance with earlier enzymological reports (Steinberg and
Avigan 1969; Bae and Paik 1997) and that indicated that
we had identified human DHCR24.
Characterization of the Human DHCR24 Gene and of
the Encoded Protein
Using the DHCR24 cDNA sequence as query, we
searched the GenBank database (National Center for
Biotechnology Information) by the BLAST algorithm
(Altschul et al. 1990) and discovered that the complete
DHCR24 gene was part of a 169,072-bp, human geno-
mic DNA clone composed of chromosome 1 sequence.
The DHCR24 gene spans 46,415 bp and comprises nine
exons and eight introns (table 2). Although it had been
predicted that the DHCR24 gene would be located on
chromosome 20 (Croce et al. 1974), it actually appeared
to be located on chromosome 1p31.1-p33.
Analysis of normalized poly(A) RNA isolated from
68 different human tissues, on a commercially available
multiple-tissue–expression array from Clontech Labo-
ratories, revealed, in adult and fetal tissues, an almost-
ubiquitous expression of DHCR24 mRNA, similar to
the expression of DHCR7 mRNA, which encodes
DHCR7 (Moebius et al. 1998; H. R. Waterham, un-
published data). Highest expression was observed in
adult adrenal gland and, to a lesser extent, in adult spinal
cord, liver, medulla oblongata, and pons as well as in
fetal liver (H. R. Waterham, unpublished data).
DHCR24 mRNA comprises an ORF of 1,548 bp pre-
dicted to encode a polypeptide of 516 amino acids with
a calculated molecular weight of 60.1 kD, with a potential
N-terminal secretory signal sequence, and with at least
one putative transmembrane helix (fig. 4). DHCR24
shows 97%, 49%, and 4% amino acid identity with its
orthologs in mouse,Caenorhabditis elegans, andA. thal-
iana, respectively. No sequence similarity to other pre-
viously identified human or yeast sterol reductases was
observed, nor did we find a consensus sequence for
NADPH binding. As is the case with plant DWF1,
DHCR24 contains a conserved domain (at residues
96–233) that is postulated to be involved in noncovalent
FAD binding, which is characteristic of a recently defined
family of FAD-dependent oxidoreductases (Mushegian
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Figure 3 Dependence of DHCR24 activity on NADPH and on
FAD. Yeast homogenates were incubated with the enzyme-assay mix
with the addition of desmosterol (see “Subjects and Methods”), in the
absence or presence of NADPH and/or FAD, as indicated. After 4 h
incubation at 37C, the production, in the assay, of cholesterol from
desmosterol was determined by GC/MS. The production of cholesterol
from desmosterol measured in the presence of NADPH was set as
100%.
and Koonin 1995; Fraaije et al. 1998). When we re-
peated the desmosterol-to-cholesterol–conversion assay,
in the presence of 20 mM FAD, in homogenates of the
DHCR24-expressing yeast strain, we did observe a two-
fold increase in activity, indicating that FAD has a func-
tional role in DHCR24 enzyme activity (fig. 3).
Sequence Analysis of DHCR24 in Patients with
Desmosterolosis
To determine whether desmosterolosis is due to mu-
tations in DHCR24, we PCR amplified and sequenced
the coding parts of the nine exons, as well as their intron
junctions, from genomic DNA from the two patients. In
patient 1, three different missense mutations were found:
one (Y471S) was inherited from the mother, and the
other two (N294T and K306N) were inherited from the
father (table 3). Both Y471 and N294 are located in the
carboxy-terminal half of DHCR24 and are invariantly
conserved among the orthologs in mouse, C. elegans,
and A. thaliana (fig. 4). K306 also is located in the car-
boxy-terminal half but is conserved only in the ortholog
of mouse, whereas a T and a Q are found at this position
in the orthologs in C. elegans and A. thaliana, respec-
tively, leaving the possibility that K306N is a polymor-
phic variant (fig. 4). Patient 2 was a homozygote for an
E191K mutation, which was confirmed by the discovery
that both parents were heterozygotes for this mutation
(table 3). E191 is located in the FAD-binding domain
and is conserved among most members of the oxido-
reductase family, including the orthologs in mouse, C.
elegans, and A. thaliana (fig. 4).
Heterologous Expression, in S. cerevisiae, of DHCR24
cDNA from Patients
To study the effects that the mutations have on
DHCR24 activity, we expressed, in S. cerevisiae, the var-
ious alleles in the patients and measured the ability of
the mutant proteins to convert desmosterol to choles-
terol. As in the severe clinical phenotype, neither of the
mutant alleles in patient 1 produced active DHCR24
(table 3). To determine whether one of the two paternal
mutations in patient 1 is a common polymorphic vari-
ant, we analyzed 50 alleles of controls of European de-
scent, but we did not detect either of the two mutations.
Therefore, the effect that either of the individual mu-
tations has on DHCR24 activity was studied by sepa-
rately expressing them in S. cerevisiae. This revealed that
both mutations affect DHCR24 activity, although the
residual activity was three to four times higher in the
K306N allele than in the N294T allele. The combination
of both mutations is required for complete deficiency
(table 3). Expression, in S. cerevisiae, of the E191K mu-
tant allele in patient 2 revealed ∼20% residual activity
(table 2), which is in good accordance with the relatively
mild clinical and biochemical phenotype of this patient.
Discussion
In this study, we have reported the humanDHCR24 gene,
identified by the similarity between the DHCR24 protein
and the recently characterized DWARF1/DIMINUTO
gene product of A. thaliana, which is involved in plant
steroid/sterol biosynthesis. We have confirmed that
DHCR24 encodes DHCR24, by functional expression,
in S. cerevisiae, of the DHCR24 cDNA. In addition, we
have demonstrated—by expression, in S. cerevisiae, of
alleles in patients—that enzyme-inactivating mutations in
DHCR24 are the cause of the cholesterol-biosynthesis
disorder desmosterolosis.
No sequence similarity between DHCR24 and other,
previously identified human, plant, or yeast sterol re-
ductases exists, which, in retrospect, explains the dif-
ficulty of identifying both the protein and its encoding
gene. Except for DHCR24, all sterol reductases—in-
cluding sterol D7-, sterol D14-, and sterol D24(28)-
reductases—belong to one family of proteins sharing a
high degree of sequence homology. These sterol reduc-
tases all have been localized to the membrane of the
endoplasmic reticulum, and all require NADPH for
their activities; both of these conditions are also true of
DHCR24. As suggested by the presence of a putative
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Table 2
Genomic Structure of DHCR24 at 1p31.1-p33
cDNA SEQUENCE (SIZE [bp])
SPLICE SITE
EXON Acceptor Donor INTRON (SIZE[bp])
1 87–231 (269) … AAGCAGgtgagcggcg IVS1 (3,115)
2 232–387 (156) gtggttgcagGTGCGG AAACAGgtgagagtag IVS2 (7,559)
3 388–493 (106) gtgtcaacagATTGTC CAGTGGgtgaggaccc IVS3 (730)
4 494–612 (119) gtctctgcagGGGGTC ACTCCGgtgagttcag IVS4 (3,479)
5 613–876 (264) tgtctcacagTCCGAA AGCAAGgtaagccagg IVS5 (14,759)
6 877–1,020 (144) gtcatttcagCTGAAT CTCCAGgtgaggcttg IVS6 (11,065)
7 1,021–1,218 (198) tgttttccagGACATT ATCCACgtgagtgggg IVS7 (424)
8 1,219–1,397 (179) gtctacccagGTCTAC GCATGGgtgagtggcc IVS8 (1,048)
9 1,398–4,149 (2,752) gcctctgcagCTTCCA … …
NOTE.—Data are for part of human clone RPII-12C17, sequenced by Genome Sequencing Center, Wash-
ington University School of Medicine, Seattle.
secretory-signal sequence, subcellular localization and
topology studies of A. thaliana DWF1 revealed a lo-
calization to the endoplasmic-reticulum membrane,
with the carboxy terminus oriented toward the cyto-
plasm (Klahre et al. 1998). In addition, Greeve et al.
(2000) recently reported a localization, to the endo-
plasmic-reticulum membrane, of the human seladin-1
protein, which appears identical to DHCR24 (also see
below).
As is the case for the activities of the other sterol
reductases, the conversion of desmosterol to cholesterol
by DHCR24 appears strictly NADPH dependent, al-
though no common consensus sequence for an NADPH-
binding site can be found in the DHCR24 amino acid
sequence. In contrast, DHCR24 appears to be a member
of a recently defined family of FAD-dependent oxido-
reductases that all share a conserved domain postulated
to be involved in either covalent or noncovalent binding
of FAD. Although FAD could not substitute for NADPH
in our enzyme-activity assay, we noted a twofold in-
crease in activity after the addition of FAD, strongly
suggesting that, in the case of DHCR24, FAD is non-
covalently linked.
Desmosterolosis is only the fourth inherited disorder
of postsqualene cholesterol biosynthesis for which the
molecular basis has been solved; the first three include
autosomal recessive Smith-Lemli-Opitz syndrome
(SLOS [MIM 270400]), which is caused by deficiency
of DHCR7 (encoded by the DHCR7 gene, at 11q13
[Fitzky et al. 1998; Wassif et al. 1998; Waterham et al.
1998; Witsch-Baumgartner et al. 2000]), and the X-
linked dominant inherited disorders Conradi-Hu¨ner-
mann-Happle syndrome (CDPX2 [MIM 302960]) and
congenital hemidysplasia with ichthyosis and limb de-
fects (CHILD) syndrome (MIM 308050), which are
caused by deficiencies of sterol D8-D7 isomerase (en-
coded by the EBP gene, at Xp11.22-23 [Braverman et
al. 1999; Derry et al. 1999]) and of sterol C-4 demethyl-
ase (encoded by the NSDHL gene, at Xq28 [Konig et
al. 2000]), respectively. SLOS is clinically characterized
by multiple morphogenic and congenital abnormalities,
including craniofacial, organ, limb/skeletal, and uro-
genital anomalies, as well as by growth retardation and
mental retardation (Kelley 2000; Kelley and Hennekam
2000; Waterham and Wanders 2000). Both CDPX2 and
CHILD syndrome clinically present with skeletal and
skin abnormalities, including stippling of epiphyses, rhi-
zomelia (shortening of long bones), ichthyosis, and hy-
perkeratosis (Herman 2000; Kelley 2000). The two pa-
tients with desmosterolosis exhibit clinical features of
all three aforementioned syndromes. Since the clinical
presentation of both patients was, however, rather dif-
ferent, the identification of additional patients will be
required for further delineation of the clinical phenotype
of desmosterolosis.
The overlap, in clinical phenotype, between the dif-
ferent cholesterol-biosynthesis disorders suggests a com-
mon mechanism underlying their pathogenesis. Indeed,
the involvement of cholesterol in embryonic develop-
ment and morphogenesis, recently discovered by its role
in the hedgehog-protein signal–transduction pathways,
provides a potential key to the pathogenesis of these
disorders (Porter et al. 1996; Hammerschmidt et al.
1997; Mann and Beachy 2000; McMahon 2000; Villa-
vicencio et al. 2000). The hedgehog proteins comprise
a family of secreted embryonic-signaling molecules in-
volved, in both vertebrates and invertebrates, in em-
bryonic patterning. In higher vertebrates, including hu-
mans, three different hedgehog proteins (Sonic, Desert,
and Indian) have been identified and have been impli-
cated in an increasing number of different developmen-
tal processes (Hammerschmidt et al. 1997; McMahon
2000; Villavicencio et al. 2000), many of which are
defective in patients with one of the cholesterol-biosyn-
thesis disorders. Although the exact role of cholesterol
in the pathways is still elusive and may occur at multiple
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Figure 4 Sequence alignment of human (Hs) DHCR24 and its orthologs in mouse (Mm), C. elegans (Ce), and A. thaliana (At), by the
CLUSTAL W program (Thompson et al. 1994). Only amino acids that are identical and conserved in at least three sequences are indicated, by
black boxes and gray boxes, respectively. Indicated above the DHCR24 sequence are conserved domains predicted to encode a secretory-signal
sequence (SS), an FAD-binding domain characteristic of the family of FAD-dependent oxidoreductases (FAD), and a membrane-associated helix
(MAH); arrowheads indicate mutations identified in patients with desmosterolosis.
levels (i.e., hedgehog-protein–signal generation, recep-
tion, transduction, and/or transport), it has been as-
sumed that perturbations of these pathways provide an
explanation of most of the congenital abnormalities as-
sociated with these disorders.
Recently, a human DWF1 homolog was reported to
exhibit a relatively low expression in affected neurons
of patients with Alzheimer disease (AD) (Greeve et al.
2000). This homolog, which, because of its lack of phys-
iological function, was named “seladin-1” (for selective
Alzheimer disease indicator 1), appears identical to
DHCR24. Overexpression of seladin-1 in PC12 cells
and in human neuroglioma H4 cells resulted in resis-
tance against AD-associated amyloid-b peptide–induced
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Table 3
Mutations in DHCR24 in Patients with Desmosterolosis—and the
Effects of Those Mutations on DHCR24 Activity
Subject and Nucleotidea (Amino Acid) Change
DHCR24
Activityb
(%)
Patient 1:
1412ArCm (Y471S) ND
881ArC  918GrCp (N294T  K306N) .8
881ArCp (N294T) 14.4
918GrCp (K306N) 49.8
Patient 2:
571GrAmp (E191K) 19.9
a Mutations inherited from the father are denoted by a superscript
“p,” and mutations inherited from the mother are denoted by a su-
perscript “m.”
b Determined by expression in S. cerevisiae, normalized to PGI ac-
tivity, and expressed as percentage of activity of wild-type DHCR24
protein; values are the means of two experiments; ND p not
detectable.
toxicity and in protection from apoptotic cell death,
respectively. On the basis of these in vitro observations,
it was suggested that high seladin-1 levels might delay
and/or prevent neurodegeneration in AD (Greeve et al.
2000); however, given our current demonstration of sel-
adin-1/DHCR24’s function in cholesterol biosynthesis,
it is unclear how to interpret these results, in light of
recent data indicating that, in fact, a reduction of cho-
lesterol biosynthesis leads to a decrease in the produc-
tion and accumulation of amyloid-b peptide and, as a
consequence, to the development of AD (Wolozin et al.
2000; Fassbender et al. 2001; Kojro et al. 2001; Wolozin
2001).
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